What is Quanterix?
Founded in 2007, Quanterix specializes in the development of ultra-sensitive digital immunoassay technology known as Simoa. This platform allows for the detection of proteins at concentrations previously undetectable by conventional methods, providing researchers and clinicians with unprecedented insights into disease progression and therapeutic efficacy. By bridging the gap between basic research and clinical diagnostics, Quanterix occupies a vital niche in the precision medicine market, enabling earlier disease detection and more personalized treatment protocols.
How much funding has Quanterix raised?
Quanterix has raised a total of $373.3M across 10 funding rounds:
Series A
$15M
Series B
$6M
Series C
$18.5M
Series D
$46M
Share Placement
$8.5M
Stock Offering
$73.8M
Stock Offering
$49.7M
Stock Offering
$69M
Debt
$2M
Stock Offering
$84.8M
Series A (2008): $15M with participation from ARCH Ventures, Bain Capital Ventures, and Flagship Pioneering
Series B (2011): $6M led by Undisclosed
Series C (2012): $18.5M supported by In-Q-Tel, Bain Capital Ventures, ARCH Ventures, and Flagship Ventures
Series D (2016): $46M featuring Hercules Capital, Cormorant Asset Management, Tufts University, Bain Capital Ventures, Trinitas Capital Management, Arch Venture Partners, and ARCH Overage Fund
Share Placement (2017): $8.5M backed by T. Rowe Price Associates
Stock Issuance/Offering (2017): $73.8M with participation from Undisclosed
Stock Issuance/Offering (2019): $49.7M led by Undisclosed
Stock Issuance/Offering (2019): $69M supported by Undisclosed
Debt (2020): $2M featuring PPP
Stock Issuance/Offering (2020): $84.8M, investors not publicly disclosed
Key Investors in Quanterix
Bain Capital Ventures
A global private investment firm with a deep focus on growth and venture capital, providing strategic operational support and flexible capital solutions to high-impact companies.
Flagship Pioneering
A Cambridge-based firm of scientists and professionals dedicated to building and scaling companies that transform human health and sustainability through pioneering innovation.
ARCH Venture Partners
A leading early-stage venture capital firm that specializes in co-founding and investing in life sciences and advanced technology companies to commercialize breakthrough research.
What's next for Quanterix?
Looking ahead, Quanterix is well-positioned to leverage its recent capital influx to accelerate the commercialization of its diagnostic suite and expand its footprint in clinical settings. The strategic focus will likely center on deepening the integration of Simoa technology into routine clinical workflows, thereby enhancing the company's competitive moat. As the demand for high-sensitivity diagnostic tools continues to rise, Quanterix's ability to maintain its technological edge will be paramount in sustaining its growth trajectory and delivering long-term value to its stakeholders.
See full Quanterix company page
